Literature DB >> 7584058

Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.

O Yamada1, M Yu, J K Yee, G Kraus, D Looney, F Wong-Staal.   

Abstract

T-cell lines (Jurkat and Molt-4) were transduced with retroviral vectors containing a hairpin ribozyme that targets a conserved sequence in the 5' transcribed leader sequence of human immunodeficiency virus (HIV) type 1. Stable cell lines were generated which constitutively and persistently expressed the ribozyme gene driven by either the Moloney retroviral long terminal repeat (LTR) or an internal human tRNA(val) promoter. There was no apparent deleterious effect of long-term ribozyme expression on cell proliferation or viability. Cells expressing ribozyme were resistant to challenge from diverse strains of HIV, including an uncloned clinical isolate. No reverse transcriptase activity or virus infectivity was detectable in the culture supernatants of Jurkat cells expressing the ribozyme driven by the tRNA(val) promoter up to 35 days after challenge with HIV-1/HXB2. Expression of the ribozyme also significantly decreased (by approximately 50- to 100-fold) the efficiency of incoming virus to synthesize viral DNA. These and previously reported results indicate that transfer and expression of the ribozyme gene interfere with both early and late events in the HIV replication cycle and confer long-term resistance to HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584058

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  22 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Authors:  Gunter Kraus; Rebeca Geffin; Gina Spruill; Andrea K Young; Rachel Seivright; Diana Cardona; Jennifer Burzawa; H James Hnatyszyn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 3.  The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.

Authors:  R Shippy; R Lockner; M Farnsworth; A Hampel
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 4.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

5.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 7.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 8.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

9.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.